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ORIGINAL ARTICLE
Background/Aims: This multicenter, open-labeled, randomized trial was performed to compare the effects of
rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic
metabolic syndrome.
Methods: In total, 351 patients who met the modified National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) criteria for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels
≥ 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg (n = 178) for
over 6 weeks. 
Results: After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%,
p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol
(- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p =
0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group. Overall, the
percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin
(87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of
insulin resistance index were not significantly different between the two groups. The safety and tolerability of the
two agents were similar. 
Conclusions: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C
goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level
goals. (Korean J Intern Med 2010;25:27-35)
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INTRODUCTION
Metabolic syndrome consists of a group of cardiovascular
risk factors, namely dyslipidemia, high blood pressure
(BP), abdominal obesity, and insulin intolerance, whose
concurrent appearance increases the risk of atherosclerotic
cardiovascular disease [1]. Using the modified National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III [ATP
III]) criteria, the prevalence of atherosclerotic cardiovascular
disease is estimated to be as high as 24.8% in Korea and iscontinuing to rapidly increase to epidemic proportions
[2]. Elevated cholesterol levels have also been shown to be
a strong risk factor for the development of coronary heart
disease (CHD). This clustering of risk factors may interact
synergistically to affect atherosclerosis and cardiovascular
events [3]. Current guidelines for lipid management stress
the importance of low-density lipoprotein cholesterol
(LDL-C) levels as the primary goal of therapy [4]; however,
a high proportion of patients, especially those having high
lipid levels, do not achieve their target LDL-C levels
despite lipid-lowering therapy [5,6].
Statins effectively lower blood cholesterol levels and
reduce the risk of cardiovascular events in many patient
types, and are therefore recommended as first-line agents
for lowering LDL-C levels [4,7]. Statins also improve other
aspects of the lipid profile, such as increasing high-density
lipoprotein cholesterol (HDL-C) and lowering triglyceride
levels to some extent. 
Rosuvastatin is a highly effective HMG-CoA reductase
inhibitor, which was registered in 2002 in Korea.
Rosuvastatin use has been previously shown in numerous
studies to be associated with greater LDL-C level reductions
as compared to atorvastatin, simvastatin, or pravastatin
use [8-10]. The primary objective of the current trial was
to compare the effects of rosuvastatin 10 mg with that of
atorvastatin 10 mg, which are the lowest-dose tablets
available, on the percentage of patients who reach the
NCEP ATP III LDL-C goal and safety in subjects with
nondiabetic metabolic syndrome after 6 weeks of
treatment. The secondary objective was to compare the
effects of rosuvastatin with that of atorvastatin on glucose
control and insulin resistance. 
METHODS
Study design
This 6-week, multicenter, randomized, open-label,
parallel-group, single-dose trial (NCT00335699) was
designed to compare the efficacy of a single dose of
rosuvastatin and atorvastatin in patients having nondiabetic
metabolic syndrome with dyslipidemia (Fig. 1). The study
was conducted from August 2005 to January 2006 at 20
medical centers in Korea. The study included a 6-week
dietary run-in period before randomization, followed by a
6-week treatment phase. Subjects entering the run-in
period were asked to follow the NCEP Step I diet and
required to discontinue any previous lipid lowering therapy.
Following the dietary lead-in period, patients with fasting
LDL-C levels ≥ 130 mg/dL to < 220 mg/dL were selected
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Figure 1. Trial design. LDL, low-density lipoprotein; HDL, high-density lipoprotein.and randomly assigned to two parallel treatment groups.
At baseline, eligible subjects were randomized 1 : 1 to
receive either rosuvastatin (Astra-Zeneca Korea, Seoul,
Korea) 10 mg or atorvastatin (Pfizer Pharmaceuticals
Korea, Seoul, Korea) 10 mg once daily at bedtime for 6
weeks. The study drug was discontinued and subjects
were removed from the study if they withdrew informed
consent, became pregnant, or developed creatine kinase
levels greater than 10 times the upper normal limit. 
The ethics committees and institutional review boards
at each participating hospital approved the study protocol.
All patients provided informed consent to participate in
this study. 
Subjects
Patients were ≥ 18 years of age and had nondiabetic
metabolic syndrome. Metabolic syndrome was defined
according to the modified NCEP ATP III criteria [11],
which requires at least three of the following: abdominal
obesity (waist circumference): men > 90 cm (36 inches),
women > 80 cm (32 inches); triglyceride levels ≥ 150
mg/dL (1.70 mmol/L); HDL-C levels: men < 40 mg/dL
(1.04 mmol/L) and women < 50 mg/dL (1.3 mmol/L); BP
≥ 130 / ≥ 85 mmHg or subject receiving antihypertensive
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Table 1. Baseline characteristics at randomization
Factors Rosuvastatin 10 mg Atorvastatin 10 mg p value
(n = 172) (n = 178)
Sex, male, % 73 (42.44) 67 (37.64) 0.359
Age, yr 60.49 ± 0.74 58.96 ± 0.75 0.148
Weight, kg 66.84 ± 0.81 66.73 ± 0.83 0.924
Height, cm 160.01 ± 0.75 158.80 ± 0.64 0.221
Systolic BP, mmHg 134.58 ± 1.15 135.73 ± 1.14 0.477
Diastolic BP, mmHg 80.16 ± 0.78 80.18 ± 0.82 0.988
Waist circumference, cm 91.81 ± 0.47 91.60 ± 0.54 0.760
Values are presented as the mean ± SE.
BP, blood pressure.
Table 2.  Changes in metabolic parameters after treatment 
Rosuvastatin 10 mg  Atorvastatin 10 mg p valuec
(n = 170) (n=176)
Baseline Treatment Baseline Treatment
Lipids, mg/dL
Total cholesterol 237.52 ± 2.07 151.70 ± 2.26b 238.55 ± 1.89 166.23 ± 2.01b < 0.0001
LDL-C 163.64 ± 1.76 84.37 ± 1.81b 163.85 ± 1.62 98.37 ± 1.76b < 0.0001
HDL-C 39.66 ± 0.54 39.15 ± 0.55 39.76 ± 0.55 38.55 ± 0.57a 0.448
Triglyceride 171.08 ± 5.20 140.92 ± 4.64b 174.75 ± 4.69 146.56 ± 4.76b 0.397
Non-HDL-C 197.85 ± 1.90 112.55 ± 2.12b 198.80 ± 1.77 127.69 ± 1.88b < 0.0001
Apolipoprotein A-1 141.95 ± 2.01 141.65 ± 1.76 141.75 ± 1.92 140.71 ± 2.43 0.756
Apolipoprotein B 117.44 ± 1.55 71.12 ± 1.69b 117.90 ± 1.38 78.62 ± 1.50b 0.001
Glucose and insulin
Glucose, mg/dL 91.08 ± 0.75 91.07 ± 0.95 93.32 ± 0.84 91.86 ± 0.88 0.541
HbA1c, % 5.88 ± 0.04 5.93 ± 0.04a 5.86 ± 0.03 5.86 ± 0.03 0.456
HOMA index 1.21 ± 0.07 1.57 ± 0.11a 1.52 ± 0.18 1.45 ± 0.11 0.465
hsCRP, mg/L 2.29 ± 0.30 2.24 ± 0.42a 2.23 ± 0.35 1.77 ± 0.26a 0.344
Values are presented as the mean ± SE.  
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1C; HOMA, homeostasis
model assessment; hsCRP, high-sensitivity C-reactive protein.
ap < 0.05 vs. baseline.
bp < 0.001 vs. baseline. 
cStatistical difference between rosuvastatin and atorvastatin after treatment. treatment; and fasting blood glucose 110 mg/dL (6.11
mmol/L) to 125 mg/dL (6.94 mmol/L). Patients were
excluded if they were pregnant or had malignancy.
Additional exclusion criteria included diabetes, and active
arterial disease such as unstable angina, myocardial
infarction, cerebrovascular accident, coronary artery
bypass surgery, or angioplasty within 2 months prior to
enrollment. After completing the 6-week dietary run-in
period, fasting LDL-C concentrations were required to be
≥ 130 mg/dL (3.36 mmol/L) to < 220 mg/dL (5.69
mmol/L) and fasting triglyceride levels were required to
be < 400 mg/dL (4.52 mmol/L). 
Assessments
Sample analysis for efficacy endpoints was performed in
the Green Cross Reference Laboratory, Yongin, Korea,
which was certified by the American College of Pathology
(LAP No. 6708401) and the National Committee for
Clinical Laboratory Standards. Blood samples from
patients who had fasted for 12 hours were collected at all
investigational sites and delivered by courier to the central
laboratory within 24 hours of blood draw. To assess the
primary efficacy endpoint, lipid parameters such as total
cholesterol, LDL-C, HDL-C, and triglyceride levels were
measured during the dietary lead-in period, at random-
ization, and 6 weeks after treatment. Additionally, levels of
apolipoprotein A-1 and B, high-sensitivity C-reactive
protein (hsCRP), insulin, glucose, and hemoglobin A1c
(HbA1c) were measured at randomization and at 6 weeks
after treatment. LDL-C levels were calculated using the
Friedewald equation (LDL-C = total cholesterol - (HDL-C
+ triglyceride/5). The insulin resistance index was
estimated using the homeostasis model assessment
(HOMA) for insulin resistance based on the following
formula: fasting serum insulin (µU/mL) × fasting plasma
glucose (mmol/L)/22.5. According to the NCEP ATP III
guidelines, the goal LDL-C level for each patient and the
proportion of patients achieving the goal in each group
was assessed. Persons with CHD or CHD risk equivalent
(Framingham 10-year CHD risk > 20%) had a LDL-C
level goal of < 100 mg/dL. Those with multiple risk factors
had a LDL cholesterol level goal of < 130 mg/dL and those
with 0 - 1 risk factor (s) had a goal LDL cholesterol of < 160
mg/dL.
Individual demographic data, physical findings, vital
signs, and adverse events were evaluated and recorded in
the given case record form. To evaluate adverse events,
various laboratory assessments including blood counts,
and hemoglobin, aspartate aminotransferase, alanine
aminotransferase, creatine kinase, electrolyte, and creatinine
levels were performed at each time point. 
Statistical analysis
One-hundred and forty-three evaluable subjects per
treatment group were required to achieve 95% power for
detecting a clinically significant difference of 6% at the 5%
two-sided level in percentage change from baseline in
30 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
Figure 2. Percent change of lipid and apolipoprotein after
treatment for 6 weeks.
LDL-C, low-density lipoprotein cholesterol; Total-C, total
cholesterol; HDL-C, high-density lipoprotein cholesterol; Apo,
apolipoprotein. Figure 3. Proportions of patients reaching different Adult
Treatment Panel III, low-density lipoprotein cholesterol (LDL-
C) level goals at 6 weeks after treatment.
aProportion of patients reaching LDL-C level goal < 100, 130 or
160 mg/dL depending on risk category at baseline.LDL-C levels at 6 weeks with an assumed standard
deviation of 14% [12]. Assuming a dropout rate of 20%
during the randomized treatment period, approximately
180 subjects were recruited to each active treatment
group. To obtain the required number of randomized
subjects (360 in total), approximately 900 subjects were
assumed to be needed for screening based on a screening
failure rate of  60%.
The primary analysis population was the last observation
carried forward on the intention-to-treat population. This
included all subjects with a baseline and at least one post-
baseline lipid level measurement. All numeric variables
were expressed as the mean ± SEM (standard error of the
mean). Efficacy endpoints were analyzed using the
unpaired t-test for continuous variables and Pearson’s chi-
square test for frequencies with 95% confidence intervals.
Multivariate logistic regression analysis was used to
evaluate the predictors for reaching target NCEP ATP III
LDL-C levels after treatment. Variables used for analysis
included the statin used, presence of coronary artery disease
and hypertension, body mass index, gender, age, waist
circumference, and lipid parameters. 
On the basis of the actual treatment received, safety
data were evaluated for all patients who received at least
one dose of study medication.
RESULTS
Subject characteristics
In total, 645 subjects were screened for participation in
this study. Of them, 370 patients entered the dietary lead-
in phase and 351 patients met the inclusion criteria and
were randomly assigned to treatment with either
rosuvastatin 10 mg or atorvastatin 10 mg (Fig. 1). One
patient was lost to follow-up and had no safety assessment.
Table 1 shows demographic data and baseline characteristics
of all 350 subjects who took at least one dose of the study
drug at baseline. In terms of demographic data and baseline
characteristics, no statistically significant differences
existed between the two treatment groups. Patients had a
mean age of 60 years in the rosuvastatin group and 58
years in the atorvastatin group. Mean body weights were
66 kg in the rosuvastatin group and 66 kg in the atorvas-
tatin group. Mean systolic and diastolic BP and waist
circumstance were comparable between the two groups
(Table 1).
A total of five patients dropped out before efficacy
assessment. Data from 346 patients were analyzed for
efficacy in the intention-to-treat population defined as
those who took at least one dose of study drug and had
lipid levels checked at baseline and follow-up. Safety
assessments were performed in 350 patients who were
randomized and available for follow-up.  
Changes in metabolic parameters
Lipid levels, glucose levels, insulin resistance indices,
and hsCRP levels at baseline and 6 weeks are shown in
Table 2. In each group, atherogenic lipid parameters
including total cholesterol, LDL-C, triglyceride, non-HDL-
C, and apolipoprotein B had significantly decreased after
6 weeks of treatment (p < 0.001 vs. baseline). Only the
atorvastatin treatment produced a modest decrease in
HDL-C. Rosuvastatin treatment significantly increased
HbA1c and the HOMA index; however, no significant
change occurred in the atorvastatin group. 
Data from two groups were analyzed for an efficacy
comparison in the intention-to-treat population. Baseline
values of all parameters were similar between the two
groups. At 6 weeks after treatment, rosuvastatin 10 mg
produced a significantly greater reduction in total
cholesterol, LDL-C, non-HDL-C, and apolipoprotein B
levels. Otherwise, no significant differences were detected
in HDL-C and apolipoprotein A-1 levels between the two
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Table 3. Percent change of glucose and insulin resistance after treatment for 6 weeks
Factors Rosuvastatin Atorvastatin p value
(n = 170) (n = 176)
Glucose 0.24 ± 0.84 - 1.12 ± 0.76 0.231
Insulin 68.14 ± 13.28 67.91 ± 18.20 0.992
HbA1c 1.08 ± 0.53 - 0.10 ± 0.28 0.048
HOMA index 69.79 ± 13.49 72.60 ± 20.84 0.910
Values are presented as the mean ± SE.
HbA1c, hemoglobin A1c; HOMA, homeostasis model assessment.groups. In addition, no significant differences were
observed with respect to glucose, HbA1c, and hsCRP
levels, and HOMA index between the rosuvastatin and
atorvastatin groups at 6 weeks (Table 2). At 6 weeks, LDL-
C absolute values decreased by 48.04 ± 14.45 mg/dL in
the rosuvastatin group and by 39.52 ± 14.42 mg/dL in the
atorvastatin group; the former reduction associated with
rosuvastatin use was significantly larger than that with
atorvastatin (p< 0.0001).
Percent changes from baseline in lipid profiles after
treatment for 6 weeks, including LDL-C, are shown in Fig.
2. Reductions in total cholesterol (- 35.94 ± 11.38 vs.
- 30.07 ± 10.46%, p < 0.0001), non-HDL-C (- 42.93 ±
13.15 vs. - 35.52 ± 11.76%, p< 0.0001), and apolipoprotein
B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.0019) levels
were larger in the rosuvastatin group as compared to the
atorvastatin group (Fig. 2). 
LDL-C target achievement
According to the reported CHD or/and CHD risk
equivalents and/or number of risk factors and/or
Framingham 10-year risk, the NCEP ATP III LDL-C target
goal was determined in each patient and the success rate
in reaching their target goal was analyzed after 6 weeks in
each group.
The percentage of patients who reached their ATP III
LDL-C level goals was higher in the rosuvastatin group
(87.6 vs. 69.9%, p < 0.001). Among them, patients having
LDL-C target cholesterol level goals of < 100 mg and <
130 mg reached their LDL-C target level goals more
frequently in the rosuvastatin group as compared to the
atorvastatin group. In contrast, in patients with a LDL-C
target level goal < 160 mg, more than 96% reached their
target goal without a significant difference between the
rosuvastatin- and atorvastatin-treated groups (Fig. 3). The
overall achievement rate for NCEP non-HDL-C level
target goals after 6 weeks of treatment was 76.08% in the
rosuvastatin group and 58.92% in the atorvastatin group
(p= 0.067).
Percent changes in glucose levels and insulin
resistance
Percent changes in glucose levels and insulin resistance
at 6 weeks are summarized in Table 3. Changes in glucose
and insulin levels were not significantly different between
the two groups; however, HbA1c levels were slightly higher
in the rosuvastatin group with marginal significance. To
evaluate insulin resistance in the two groups, the HOMA
index was calculated. At 6 weeks, the HOMA index increased
in both groups and the difference between groups was not
significant. 
Safety
Both rosuvastatin 10 mg and atorvastatin 10 mg were
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Table 4. Most common treatment-related adverse
events (≥ 1% in any treatment group) during the
treatment period
Adverse events Rosuvastatin Atorvastatin
(n = 172) (n = 178)
Any adverse events 13 (7.56) 9 (5.06)
Serious adverse events 1 (0.58) 2 (1.12)
Drug related adverse events 0 (0.00) 5 (2.81)
Adverse events which caused 
0 (0.00) 1 (0.56)
discontinuation of the study
Values are presented as number (%). 
Table 5. Adjusted odds ratios for LDL-cholesterol goal achievement after treatment for 6 weeks
Factors Odds ratio (95% confidence interval) Standard error p value
Age, yr 0.997 (0.966 - 1.029) 0.016 0.850
Sex, male 0.424 (0.214 - 0.842) 0.350 0.014
Hypertension 1.025 (0.434 - 2.421) 0.439 0.955
Coronary artery disease 3.806 (1.959 - 7.391) 0.339 < 0.001
Body mass index ≥ 25 0.669 (0.353 - 1.267) 0.326 0.217
Waist circumference > 90 cm 1.445 (0.703 - 2.968) 0.368 0.317
Total cholesterol ≥ 230 mg/dL 0.885 (0.390 - 2.006) 0.418 0.769
LDL-cholesterol ≥ 160 mg/dL 0.446 (0.208 - 0.960) 0.391 0.039
Treatment, rosuvastatin 3.26 (1.800 - 5.906) 0.303 < 0.001
LDL, low-density lipoprotein.well tolerated, with similar incidences of adverse events.
During the treatment period, 13 subjects in the rosuvastatin
group and 9 subjects in the atorvastatin group reported
adverse events (Table 4). The most frequent adverse
events in the rosuvastatin group were edema and dizziness,
both with incidences of 1.16%. Only five adverse events
were reported in the atorvastatin group as related to the
study drug; myalgia was reported in one case (0.56%). All
adverse events were mild, developed within 2 weeks after
starting treatment, had no action taken, and resolved
spontaneously. No drug-related adverse effects were
observed in the rosuvastatin group. Also, no patient had
an increase in alanine aminotransferase level > 3 times
the upper limit of normal or rhabdomyolysis.
Predictors for LDL-C level goal achievement at 6
weeks
Overall, the percentage of patients who reached NCEP
ATP III LDL-C target level goals was higher in the
rosuvastatin group as compared to the atorvastatin group.
Univariate analysis showed that patients with target
LDL-C levels at 6 weeks tended to be rosuvastatin-treated
and have coronary artery disease. Multivariate logistic
regression analyses that included age, gender, statin,
coronary artery disease, hypertension, body mass index,
waist circumference, baseline total cholesterol levels, and
triglyceride levels showed that rosuvastatin treatment, the
presence of coronary artery disease, female gender, lower
total cholesterol level, and lower LDL-C levels at baseline
were independent predictors for achievement of target
LDL-C levels at 6 weeks (Table 5). 
DISCUSSION
This study evaluated the comparative efficacy of the
lowest doses available for two effective statins, rosuvastatin
and atorvastatin, in Korean patients with nondiabetic
metabolic syndrome. 
Rosuvastatin 10 mg was more effective than atorvastatin
10 mg in reducing LDL-C levels in subjects with nondiabetic
metabolic syndrome after 6 weeks of treatment. Consistent
with the greater reductions in LDL-C levels, more patients
in the rosuvastatin group achieved LDL-C level goals
as compared to the atorvastatin group. Otherwise, no
significant difference was observed in glucose levels and
insulin resistance. 
Metabolic syndrome, especially in the presence of high
LDL-C levels, is already known to increase the risk of
cardiovascular mortality and morbidity [13]. Statins are
effective in decreasing LDL-C levels in patients with
dyslipidemia. Survey studies have demonstrated that in
real-world settings, only 67% of patients with treated
dyslipidemia reach their LDL-C target level goals [14]. In
this study, rosuvastatin treatment was associated with
reaching recommended LDL-C level goals in a higher
percentage of patients overall as compared to atorvastatin
(87.6 vs. 69.9%). In particular, rosuvastatin was more
effective in patients requiring more intensive LDL-C level
lowering to less than 100 or 130 mg/dL. In high-risk
patients with stronger targets of LDL-C levels < 100
mg/dL, rosuvastatin brought 83% of patients in this trial
to the ATP III LDL-C level goal, which was higher than
achieved in other studies conducted in South-Asian (76%)
and Hispanic-American (61%) patients [15,16]. Both
statins, however, were effective in patients with high
target LDL-C level goals < 160 mg/dL. These data
highlight the importance of using highly effective statins
in high-risk patients to enable them to achieve their lower
NCEP ATP III LDL-C level goals. 
With respect to other elements of the lipid profile,
improvements in total cholesterol, apolipoprotein B, and
non-HDL-C levels were also significantly greater with
rosuvastatin as compared to atorvastatin, whereas changes
in HDL-C, triglyceride, and apolipoprotein A1 levels were
similar in both treatment groups. Unlike other studies in
which rosuvastatin effectively raised HDL-C levels [9,15],
HDL-C levels in this study were not effectively improved
in either group [9].
Metabolic syndrome is associated with an increased risk
of both insulin resistance and diabetes [17]. Additionally,
changes in the insulin resistance index were investigated
by evaluating the HOMA index, which is a positive predictor
of metabolic syndrome [18]. Studies in an animal model of
insulin resistance suggest that rosuvastatin treatment
increases whole-body and peripheral tissue insulin
sensitivity via improved cellular insulin signal transduction
[19]. In contrast, in our study conducted in nondiabetic
subjects, a tendency was detected for an increased HOMA
index in both treatment arms. Major changes in this
parameter were attributable to high increases in insulin
concentrations. The degrees of percent change in fasting
glucose, insulin concentrations, and HOMA index were
not significantly different between the rosuvastatin and
atorvastatin treatment groups. Thus, further studies are
needed to elucidate the effects of statins on glucose
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under diabetic or nondiabetic conditions. 
A multivariate analysis was performed to determine
independent predictors of LDL-C goal achievement at 6
weeks. Overall, sex, the presence of coronary artery
disease, LDL-C levels, and rosuvastatin treatment were
predictive of target LDL-C achievement. Among these
factors, rosuvastatin was the strongest predictor, with an
odds ratio of 3.26. Moreover, the presence of coronary
artery disease was an independent predictor of achieving
target LDL-C levels. These patients were assumed to have
been more likely to take interest in diet control or exercise
than patients without coronary artery disease. 
Although the findings of this study are provocative,
this study has important limitations. Recently, intensive
regimens with 80 mg of atorvastatin or 20 mg of rosuvastatin
have become available in Korea and produce greater
reductions in atherosclerotic lipoprotein levels, which is
particularly useful in patients with established coronary
artery disease or acute coronary syndrome. Further studies
comparing statins across dose ranges in patients not
reaching their target goal with low-dose statins are
required. Additionally, although changes metabolic
parameters were not the primary endpoint of this study, a
trend toward differences in blood glucose levels was
observed between the two statins. Further studies are
needed to elucidate the metabolic effects of statins. 
In conclusion, this study demonstrated that rosuvastatin
10 mg is significantly more effective than atorvastatin 10
mg in reducing LDL-C levels in patients with nondiabetic
metabolic syndrome, especially among those with lower
NCEP ATP III target level goals. Both statins were well
tolerated.  
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